Prospects for repurposing CNS drugs for cancer treatment

Oncology Reviews

Volumn 13, Issue 1, 2019, Pages 37-42

  Abdelaleem, Mohamed ^a   Ezzat, Hossam ^a   Osama, Muhammed ^a   Megahed, Adel ^a   Alaa, Waleed ^a   Gaber, Ahmed ^a   Shafei, Ayman ^a   Refaat, Alaa ^a,b,c  

^a Armed Forces College of Medicine   (Egypt)

^b MISR INTERNATIONAL UNIVERSITY   (Egypt)

^c KOBE UNIVERSITY   (Japan)

Author keywords

Cancer; CNS drug; Repositioning; Repurposable drugs

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; IMIPRAMINE; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; TRIFLUOPERAZINE; VALPROIC ACID;

ACUTE MYELOID LEUKEMIA; BLADDER CANCER; BREAST CANCER; BURKITT LYMPHOMA; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG REPOSITIONING; DRUG RESEARCH; GLIOBLASTOMA; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; METASTASIS; MOUTH CANCER; NEUROENDOCRINE CARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SMALL CELL LUNG CANCER; TREATMENT INDICATION; UTERINE CERVIX CANCER;

EID: 85067838450     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.4081/oncol.2019.411     Document Type: Review

References (72)

1. World Health Organization. WHO | Cancer Factsheet. Who [Internet]. 2018; Available from: http://www.who.int/cancer/en/
2. Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, et al. The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol. 2012;30(24):3012-9.
3. Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB. Cancer drug discovery by repurposing: Teaching new tricks to old dogs. Trends Pharmacol Sci. 2013;34(9):508-17.
4. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience. 2014;8(1):442.
5. Matthews SJ, McCoy C. Peginterferon alfa-2a: A review of approved and investigational uses. Clin Ther [Internet]. 2004;26(7):991-1025.
6. Verbaanderd C, Maes H, Schaaf MB, Sukhatme VP, Pantziarka P, Sukhatme V, et al. Repurposing drugs in oncology (ReDO)-Chloroquine and hydroxychloroquine as anti-cancer agents. Ecancermedicalscience. 2017;11:781.
7. Pantziarka P, Bouche G, Sukhatme V, Meheus L, Rooman I, Sukhatme VP. Repurposing drugs in oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct;10:680.
8. Pantziarka P, Bouche G, Meheus L, Sukhatme VVP, Sukhatme VVP. Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent. Ecancer [Internet]. 2014;8:443.
9. Pantziarka P, Bouche G, Meheus L, Sukhatme VVP, Sukhatme VVP. Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent. Ecancer [Internet]. 2014;8:443.
10. Pantziarka P, Bouche G, Sukhatme V, Meheus L, Rooman I, Sukhatme VP. Repurposing drugs in oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience [Internet]. 2016;10:513.
11. Pantziarka P, Bouche G, Sukhatme V, Meheus L, Rooman I, Sukhatme VP. Repurposing drugs in oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience [Internet]. 2016;10:610.
12. Pantziarka P, Bouche G, Sukhatme V, Meheus L, Rooman I, Sukhatme VP. Repurposing drugs in oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience [Internet]. 2016;10:521.
13. Forget P, Berlière M, van Maanen A, Duhoux FP, Machiels JP, Coulie PG, et al. Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial. Med Hypotheses. 2013;81(4):707-12.
14. Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas-Full Text View-ClinicalTrials.gov [Internet]. 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT02115074
15. Barak Y, Achiron A, Mandel M, Mirecki I, Aizenberg D. Reduced cancer incidence among patients with schizophrenia. Cancer [Internet]. 2005 Dec 15 [cited 2018 Apr 25];104(12):2817-21. Available from: http://doi.wiley.com/10.1002/cncr.21574
16. Fond G, Macgregor A, Attal J, Larue A, Brittner M, Ducasse D, et al. Antipsychotic drugs: Pro-cancer or anti-cancer? A systematic review. Med Hypotheses 2012;79(1):38-42.
17. Pereira VS, Hiroaki-Sato VA. A brief history of antidepressant drug development: from tricyclics to beyond ketamine. Acta Neuropsychiatr 2018;1-16.
18. Elmaci I, Altinoz MA. Targeting the cellular schizophrenia. Likely employment of the antipsychotic agent pimozide in treatment of refractory cancers and glioblastoma. Crit Rev Oncol Hematol 2018;128:96-109.
19. Roney MSI, Park SK. Antipsychotic dopamine receptor antagonists, cancer, and cancer stem cells. Arch Pharm Res 2018;41(4):384-408.
20. Ban TA. Fifty years chlorpromazine: A historical perspective. Neuropsychiatr Dis Treat. 2007;3(4):495-500.
21. Brown WA, Rosdolsky M. The clinical discovery of imipramine. Am J Psychiatry. 2015;172(5):426-9.
22. Drug CategoriesBrowse DrugBank Categories-DrugBank [Internet]. Available from: https://www.drugbank.ca/categories
23. Pearce JMS. Bromide, the first effective antiepileptic agent. J Neurol Neurosurg Psychiatry. 2002;72(3):412.
24. López-Muñoz F, Ucha-Udabe R, Alamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat 2005 Dec;1(4):329-43.
25. Smith M, Wilcox KS, White HS. Discovery of Antiepileptic Drugs. Neurotherapeutics. 2007;4(1):12-7.
26. Arzimanoglou A, Ben-Menachem E, Cramer J, Glauser T, Seeruthun R, Harrison M. The evolution of antiepileptic drug development and regulation. Epileptic Disord 2010;12(1):3-15.
27. Gerlach AC, Krajewski JL. Antiepileptic drug discovery and development: What have we learned and where are we going? Pharmaceuticals. 2010 Sep;3(9):2884-99.
28. Henry TR. The history of valproate in clinical neuroscience. Psychopharmacol Bull 2003;37 Suppl 2:5-16.
29. Munson JM, Fried L, Rowson SA, Bonner MY, Karumbaiah L, Diaz B, et al. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci Transl Med. 2012 Mar;4(127):127ra36-127ra36.
30. Shchors K, Massaras A, Hanahan D. Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit. Cancer Cell. 2015;28(4):456-71.
31. Rajamanickam S, Panneerdoss S, Gorthi A, Timilsina S, Onyeagucha B, Kovalskyy D, et al. Inhibition of FoxM1-Mediated DNA repair by imipramine blue suppresses breast cancer growth and metastasis. Clin Cancer Res. 2016;22(14):3524-36.
32. Yang WH, Su YH, Hsu WH, Wang CC, Arbiser JL, Yang MH. Imipramine blue halts head and neck cancer invasion through promoting F-box and leucine-rich repeat protein 14-mediated Twist1 degradation. Oncogene. 2016;35(18):2287-98.
33. Klingenberg M, Becker J, Eberth S, Kube D, Wilting J. The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma. Mol Cancer Ther [Internet]. 2014;13(4):833-41.
34. Metts J, Bradley HL, Wang Z, Shah NP, Kapur R, Arbiser JL, et al. Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. Sci Rep. 2017;7(1):4447.
35. Laidlaw KME, Berhan S, Liu S, Silvestri G, Holyoake TL, Frank DA, et al. Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget [Internet]. 2016;7(32):51651-64.
36. Ghorab MM, Alsaid MS, Samir N, Abdel-Latif GA, Soliman AM, Ragab FA, et al. Aromatase inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and molecular modeling studies of novel phenothiazine derivatives carrying sulfonamide moiety as hybrid molecules. Eur J Med Chem. 2017;134:304-15.
37. Zong D, Zielinska-Chomej K, Juntti T, Mörk B, Lewensohn R, Haag P, et al. Harnessing the lysosome-dependent antitumor activity of phenothiazines in human small cell lung cancer. Cell Death Dis. 2014;5(3):e1111-e1111.
38. Wu CH, Bai LY, Tsai MH, Chu PC, Chiu CF, Chen MY, et al. Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-A drug repurposing strategy. Sci Rep. 2016;6:27540.
39. Torres-Piedra M, Figueroa M, Hernández-Abreu O, Ibarra-Barajas M, Navarrete-Vázquez G, Estrada-Soto S. Vasorelaxant effect of flavonoids through calmodulin inhibition: Ex vivo, in vitro, and in silico approaches. Bioorganic Med Chem. 2011;19(1):542-6.
40. Kang S, Hong J, Lee JM, Moon HE, Jeon B, Choi J, et al. Trifluoperazine, a Well-Known Antipsychotic, Inhibits Glioblastoma Invasion by Binding to Calmodulin and Disinhibiting Calcium Release Channel IP 3 R. Mol Cancer Ther [Internet]. 2017;16(1):217-27.
41. Wen Y, Zhang Y, Li J, Luo F, Huang Z, Liu K. Low concentration trifluoperazine promotes proliferation and reduces calcium-dependent apoptosis in glioma cells. Sci Rep. 2018;8(1):1147.
42. Yeh CT, Wu ATH, Chang PMH, Chen KY, Yang CN, Yang SC, et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med. 2012;186(11):1180-8.
43. Pulkoski-Gross A, Li J, Zheng C, Li Y, Ouyang N, Rigas B, et al. Repurposing the Antipsychotic Trifluoperazine as an Antimetastasis Agent. Mol Pharmacol 2015;87(3):501-12.
44. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, et al. SuperCYP: A comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2009;38:D237-43.
45. Bertolesi GE. The Ca2+ Channel Antagonists Mibefradil and Pimozide Inhibit Cell Growth via Different Cytotoxic Mechanisms. Mol Pharmacol 2002;62(2):210-9.
46. Mapes J, Anandan L, Li Q, Neff A, Clevenger C V., Bagchi IC, et al. Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis. J Biol Chem. 2018;293(8):2850-64.
47. Chen J-J, Cai N, Chen G-Z, Jia C-C, Qiu D-B, Du C, et al. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma. Oncotarget 2017;8(11):17593-609.
48. Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, et al. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes and Cancer. 2012;3:503-11.
49. Szalowska E, Van Der Burg B, Man HY, Hendriksen PJM, Peijnenburg AACM. Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices. Lobaccaro JMA, editor. PLoS One. 2014;9(1):e86795.
50. Ji MM, Wang L, Zhan Q, Xue W, Zhao Y, Zhao X, et al. Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation. Autophagy. 2015;11(12):160-2171.
51. Espinoza-Zamora JR, Labardini-Méndez J, Sosa-Espinoza A, López-González C, Vieyra-García M, Candelaria M, et al. Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study. Expert Opin Investig Drugs. 2017;26(4):481-7.
52. Chou YW, Chaturvedi NK, Ouyang S, Lin FF, Kaushik D, Wang J, et al. Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Lett. 2011;311(2):177-86.
53. Witt D, Burfeind P, von Hardenberg S, Opitz L, Salinas-Riester G, Bremmer F, et al. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. Carcinogenesis. 2013;34(5):1115-24.
54. Tran LNK, Kichenadasse G, Butler LM, Centenera MM, Morel KL, Ormsby RJ, et al. The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer. Mol Cancer Ther 2017;16(12):molcanther.0074.2017.
55. Gan CP, Hamid S, Hor SY, Zain RB, Ismail SM, Wan Mustafa WM, et al. Valproic acid: Growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck [Internet]. 2012;34(3):344-53.
56. Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, et al. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. BMC Cancer. 2016;16(1):918.
57. Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid. ClinicaltrialsGov [Internet]. 2015;2015-6. Available from: https://clinicaltrials. gov/show/NCT02608736
58. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol. 2010;12(4):328-40.
59. Tseng J-H, Chen C-Y, Chen P-C, Hsiao S-H, Fan C-C, Liang Y-C, et al. Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. Oncotarget [Internet]. 2017;8(9):14666-79.
60. Seizure Treatment in Glioma-Full Text View-ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials. gov/ct2/show/NCT03048084
61. Zapotocky M, Mejstrikova E, Smetana K, Stary J, Trka J, Starkova J. Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically. Cancer Lett. 2012;319(2):144-53.
62. Cerna T, Hrabeta J, Eckschlager T, Frei E, Schmeiser HH, Arlt VM, et al. The histone deacetylase inhibitor valproic acid exerts a synergistic cytotoxicity with the DNA-damaging drug ellipticine in neuroblastoma cells. Int J Mol Sci. 2018;19(1): 164.
63. Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Internet]. Clinicaltrials.Gov. 2004. p. 3/1/2004. Available from: http://clinicaltrials.gov/show/NCT00079378
64. Fredly H, Ersvær E, Kittang AO, Tsykunova G, Gjertsen BT, Bruserud O. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenetics. 2013;5(1):13.
65. Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia [Internet]. Clinicaltrials.Gov. 2015. p. 2015-null. Available from: https://clinicaltrials.gov/show/NCT02144623
66. Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, Schelman WR, et al. A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma. Oncologist 2011;16(6):835-43.
67. Liu S, Liang B, Jia H, Jiao Y, Pang Z, Huang Y. Evaluation of cell death pathways initiated by antitumor drugs melatonin and valproic acid in bladder cancer cells. FEBS Open Bio. 2017;7(6):798-810.
68. Saha SK, Yin Y, Kim K, Yang GM, Dayemv AA, Choi HY, et al. Valproic acid induces endocytosis-mediated doxorubicin internalization and shows synergistic cytotoxic effects in hepatocellular carcinoma cells. Int J Mol Sci. 2017;18(5):1048.
69. Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, et al. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget 2016;7(7):7715-31.
70. Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment-a Pilot [Internet]. Clinicaltrials.Gov. 2010. p. 5/1/2010-1/1/2013. Available from: http://clinicaltrials.gov/show/NCT01007695
71. Venkataramani V, Rossner C, Iffland L, Schweyer S, Tamboli IY, Walter J, et al. Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem. 2010;285(14):10678-89.
72. Li J, Bonifati S, Hristov G, Marttila T, Valmary-Degano S, Stanzel S, et al. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med. 2013;5(10):1537-55.